These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9779780)

  • 21. CCR5 HIV-1 vertical transmission. Women and Infants Transmission Study Group.
    Shearer WT; Kalish LA; Zimmerman PA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Feb; 17(2):180-1. PubMed ID: 9473022
    [No Abstract]   [Full Text] [Related]  

  • 22. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.
    Hladik F; Liu H; Speelmon E; Livingston-Rosanoff D; Wilson S; Sakchalathorn P; Hwangbo Y; Greene B; Zhu T; McElrath MJ
    J Virol; 2005 Sep; 79(18):11677-84. PubMed ID: 16140745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maternal SDF1 3'A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission.
    John GC; Rousseau C; Dong T; Rowland-Jones S; Nduati R; Mbori-Ngacha D; Rostron T; Kreiss JK; Richardson BA; Overbaugh J
    J Virol; 2000 Jun; 74(12):5736-9. PubMed ID: 10823884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of influenza virus vaccine on the expression of human immunodeficiency virus co-receptor CCR5.
    Rucker RP; Day NK; Good RA; Kamchaisatian W; Emmanuel P; Sleasman JW; Mayeski C; Dinglasan E; Haraguchi S; Tangsinmankong N
    Ann Allergy Asthma Immunol; 2004 Sep; 93(3):272-6. PubMed ID: 15478388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection.
    Sei S; Boler AM; Nguyen GT; Stewart SK; Yang QE; Edgerly M; Wood LV; Brouwers P; Venzon DJ
    AIDS; 2001 Jul; 15(11):1343-52. PubMed ID: 11504955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
    Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
    J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of polymorphisms of chemokine receptors on neurodevelopment and the onset of encephalopathy in children with perinatal HIV-1 infection.
    Llorente A; Brouwers P; Thompson B; Cheng I; Macmillan C; Larussa P; Mofenson L; Blasini I; Chase C
    Appl Neuropsychol; 2006; 13(3):180-9. PubMed ID: 17361671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CCL3L1 and HIV/AIDS susceptibility.
    Bhattacharya T; Stanton J; Kim EY; Kunstman KJ; Phair JP; Jacobson LP; Wolinsky SM
    Nat Med; 2009 Oct; 15(10):1112-5. PubMed ID: 19812561
    [No Abstract]   [Full Text] [Related]  

  • 31. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus type 1 disease progression.
    de Roda Husman AM; van Rij RP; Blaak H; Broersen S; Schuitemaker H
    J Infect Dis; 1999 Oct; 180(4):1106-15. PubMed ID: 10479137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of a CCR5 defective allele in pediatric HIV-1 infection.
    Romiti ML; Colognesi C; Cancrini C; Mas A; Berrino M; Salvatori F; Orlandi P; Jansson M; Palomba E; Plebani A; Bertran JM; Hernandez M; de Martino M; Amoroso A; Tovo PA; Rossi P; Espanol T; Scarlatti G
    Mol Med; 2000 Jan; 6(1):28-36. PubMed ID: 10803406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of the CCR5delta32 mutation with improved response to antiretroviral therapy.
    Valdez H; Purvis SF; Lederman MM; Fillingame M; Zimmerman PA
    JAMA; 1999 Aug; 282(8):734. PubMed ID: 10463706
    [No Abstract]   [Full Text] [Related]  

  • 34. RANTES production from CD4+ lymphocytes correlates with host genotype and rates of human immunodeficiency virus type 1 disease progression.
    Paxton WA; Neumann AU; Kang S; Deutch L; Brown RC; Koup RA; Wolinsky SM
    J Infect Dis; 2001 Jun; 183(11):1678-81. PubMed ID: 11343219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
    Dolan MJ; Kulkarni H; Camargo JF; He W; Smith A; Anaya JM; Miura T; Hecht FM; Mamtani M; Pereyra F; Marconi V; Mangano A; Sen L; Bologna R; Clark RA; Anderson SA; Delmar J; O'Connell RJ; Lloyd A; Martin J; Ahuja SS; Agan BK; Walker BD; Deeks SG; Ahuja SK
    Nat Immunol; 2007 Dec; 8(12):1324-36. PubMed ID: 17952079
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of the CCR5-Delta32 HIV resistance allele and new mutations of the CCR5 gene in different Tunisian populations.
    Jlizi A; Edouard J; Fadhlaoui-Zid K; Frigi S; Debré P; Slim A; Theodorou I; El Gaaied AB; Carpentier W
    Hum Immunol; 2007 Dec; 68(12):993-1000. PubMed ID: 18191728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.
    Pasi KJ; Sabin CA; Jenkins PV; Devereux HL; Ononye C; Lee CA
    Br J Haematol; 2000 Oct; 111(1):136-42. PubMed ID: 11091193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCR5 chemokine receptor polymorphism in patients with HIV-1 from Western India.
    Shankarkumar A; Shankarkumar U; Ghosh K
    J Acquir Immune Defic Syndr; 2011 Jun; 57(2):e21. PubMed ID: 21709449
    [No Abstract]   [Full Text] [Related]  

  • 39. Relationship between CCR5
    Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
    Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Host genetic background at CCR5 chemokine receptor and vitamin D receptor loci and human immunodeficiency virus (HIV) type 1 disease progression among HIV-seropositive injection drug users.
    Barber Y; Rubio C; Fernández E; Rubio M; Fibla J
    J Infect Dis; 2001 Nov; 184(10):1279-88. PubMed ID: 11679916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.